Rion Co., Ltd. (JP:6823)
:6823
Top Page
Rion Co., Ltd.
(6823)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥3,113.00
▲(15.68% Upside)
Action:DowngradedDate:10/30/25
Rion Co., Ltd. has a strong financial foundation with robust revenue growth and cash flow generation. However, the technical indicators suggest a bearish trend, which could pose short-term risks. The stock appears undervalued with a low P/E ratio and an attractive dividend yield, making it a potentially appealing investment for value-oriented investors.
Positive Factors
Revenue Growth
A 61% year-on-year revenue increase signals durable demand for Rion's measurement and medical device offerings. Sustained top-line expansion supports scale economies, deeper market penetration across industrial and healthcare end markets, and provides recurring opportunities to reinvest in product development and distribution.
Negative Factors
Slight Margin Compression
Even modest downward pressure on gross margin reduces the operating cushion against cost inflation or competitive pricing. If the trend continues, it could constrain reinvestment capacity and reduce the conversion of revenue growth into incremental net income and free cash flow over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 61% year-on-year revenue increase signals durable demand for Rion's measurement and medical device offerings. Sustained top-line expansion supports scale economies, deeper market penetration across industrial and healthcare end markets, and provides recurring opportunities to reinvest in product development and distribution.
Read all positive factors
Rion Co., Ltd. (6823) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥35.06B
Dividend Yield2.93%
Average Volume (3M)26.46K
Price to Earnings (P/E)10.2
Beta (1Y)1.11
Revenue Growth6.72%
EPS Growth20.01%
CountryJP
Employees1,026
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)64.65
Shares Outstanding12,347,700
10 Day Avg. Volume21,140
30 Day Avg. Volume26,463
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)0.96
Price to Sales (P/S)1.09
P/FCF Ratio14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)275.7
Revenue Forecast (FY)¥29.50B
Rion Co., Ltd. Business Overview & Revenue Model
Company Description
Rion Co., Ltd. manufactures, sells, and maintains hearing instruments, medical equipment, sound and vibration measuring instruments, particle counters, and related parts and equipment in Japan. The company's audiological equipment includes hearing...
How the Company Makes Money
Rion makes money primarily by selling hardware products across two main domains: (1) measurement instruments and related systems (e.g., sound level meters, noise and vibration measurement equipment, data acquisition/analysis solutions) to corporat...
Rion Co., Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.15B | 27.88B | 25.73B | 23.87B | 22.64B | 20.47B |
| Gross Profit | 13.97B | 15.35B | 14.33B | 12.69B | 12.22B | 11.11B |
| EBITDA | 5.46B | 5.28B | 4.38B | 3.59B | 3.82B | 2.96B |
| Net Income | 3.05B | 2.86B | 2.65B | 1.80B | 2.23B | 1.64B |
Balance Sheet | ||||||
| Total Assets | 38.98B | 39.13B | 37.40B | 34.81B | 33.42B | 30.68B |
| Cash, Cash Equivalents and Short-Term Investments | 6.16B | 6.01B | 5.03B | 5.37B | 7.72B | 6.44B |
| Total Debt | 1.73B | 11.73M | 21.88M | 28.46M | 40.07M | 52.95M |
| Total Liabilities | 7.36B | 7.70B | 8.19B | 8.20B | 8.14B | 6.96B |
| Stockholders Equity | 31.62B | 31.44B | 29.21B | 26.61B | 25.29B | 23.73B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.14B | 725.98M | 473.30M | 2.31B | 1.24B |
| Operating Cash Flow | 0.00 | 3.44B | 2.86B | 1.78B | 2.84B | 2.06B |
| Investing Cash Flow | 0.00 | -1.69B | -2.65B | -3.25B | -951.93M | -1.14B |
| Financing Cash Flow | 0.00 | -748.84M | -565.55M | -577.32M | -541.83M | -566.42M |
Rion Co., Ltd. Technical Analysis
Positive
2691.00
Price Trends
2873.20
Negative
2735.15
Positive
2657.86
Positive
Market Momentum
-25.43
Positive
48.40
Neutral
84.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6823, the sentiment is Positive. The current price of 2691 is below the 20-day moving average (MA) of 2875.95, below the 50-day MA of 2873.20, and above the 200-day MA of 2657.86, indicating a neutral trend. The MACD of -25.43 indicates Positive momentum. The RSI at 48.40 is Neutral, neither overbought nor oversold. The STOCH value of 84.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6823.
Rion Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥20.79B | 15.12 | ― | 3.02% | -4.36% | -14.92% | |
69 Neutral | ¥35.06B | 10.15 | ― | 2.93% | 6.72% | 20.01% | |
68 Neutral | ¥101.21B | 26.70 | ― | 2.31% | 4.36% | 79.43% | |
65 Neutral | ¥248.91B | 36.37 | ― | 1.92% | 4.31% | 96.31% | |
63 Neutral | ¥15.25B | 14.76 | ― | 3.12% | 3.59% | -163.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥143.71B | 28.05 | 2.42% | 3.73% | 0.04% | ― |
* Healthcare Sector Average
JP:6823
Rion Co., Ltd.
2,843.00
418.66
17.27%
JP:6523
PHC Holdings Corp.
1,134.00
134.27
13.43%
JP:4549
Eiken Chemical Co., Ltd.
3,070.00
830.52
37.09%
JP:6678
Techno Medica Co., Ltd.
2,440.00
685.00
39.03%
JP:6849
Nihon Kohden Corporation
1,491.00
-493.66
-24.87%
JP:7600
Japan Medical Dynamic Marketing, Inc.
579.00
9.00
1.58%
Rion Co., Ltd. Corporate Events
Rion Reshapes Executive and Management Ranks Across Group Operations
Feb 16, 2026
Rion Co., Ltd. has announced a series of senior personnel changes effective April 1, 2026, including new roles for several executive officers overseeing corporate planning, research and development, personnel and general affairs, and production. T...
Rion Posts Steady Nine-Month Earnings and Lifts Dividend Forecast for FY2025
Jan 29, 2026
Rion Co., Ltd. reported consolidated net sales of ¥20,553 million for the nine months ended December 31, 2025, a slight 0.3% year-on-year increase, with operating profit essentially flat at ¥3,065 million and ordinary profit at ¥3,1...
Rion Raises Annual Dividend Forecast on Stable Earnings Outlook
Jan 29, 2026
Rion Co., Ltd. has revised its dividend forecast for the fiscal year ending March 31, 2026, raising its planned annual dividend from 70 yen to 85 yen per share by increasing the year-end dividend from 35 yen to 50 yen. Management cited a business ...
Rion to Deepen Employee Share Ownership with Higher Incentives and Broader Eligibility
Jan 26, 2026
Rion Co., Ltd. has resolved to significantly enhance its employee stock ownership plan to strengthen employee engagement and promote long-term corporate value creation by more closely aligning employees’ interests with shareholders. Effectiv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.